2 results match your criteria: "Australian Clinical Labs (WA)[Affiliation]"
The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Pathology
December 2017
Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Crawley, Australia; St John of God Subiaco Hospital, Subiaco, Australia.
Cancer stem-like cells are highly tumourigenic cells that can repopulate entire tumours after apparent successful treatment. Recent evidence suggests they interact with other cells in the tumour microenvironment, including immune cell subsets, to enhance their survival. The aim of this study was to determine whether the expression of immune cell markers in primary colon cancer impacts the prognostic significance of cancer stem-like cell marker expression.
View Article and Find Full Text PDFA cautionary note regarding detection of PD-L1 expression by tumour-associated macrophages.
Gynecol Oncol Rep
May 2017
Australian Clinical Labs (WA), 12 Salvado Rd, Subiaco, WA 6008, Australia.